Home > Insider Trading > Filing (0001104659-22-120780)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1781174	Acrivon Therapeutics Inc.	ACRV	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1315082	Ra Capital Healthcare Fund Lp	200 Berkeley Street, 18Th Floor Boston MA 02116	Yes	No	Yes	No
1346824	Ra Capital Management, L.p.	200 Berkeley Street, 18Th Floor Boston MA 02116	Yes	No	Yes	No
1384859	Peter Kolchinsky	C/O Ra Capital Management, L.p. 200 Berkeley Street, 18Th Floor Boston MA 02116	Yes	No	Yes	No
1619841	M. Rajeev Shah	C/O Ra Capital Management, L.p. 200 Berkeley Street, 18Th Floor Boston MA 02116	Yes	No	Yes	No
1825376	Ra Capital Nexus Fund Ii, L.p.	200 Berkeley Street, 18Th Floor Boston MA 02116	Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-11-17	994,706	$0.00	994,706	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2022-11-17	3,389,500	$12.50	4,384,206	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2022-11-17	426,302	$0.00	426,302	No	4	C	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	C	Indirect	See Footnotes

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2022-11-17	2,452,947	$0.00	994,706	$0.00
Common Stock	Series B Preferred Stock	Disposition	2022-11-17	1,051,263	$0.00	426,302	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

On November 17, 2022 each share of Series B Preferred Stock (the "Preferred Stock") converted into Common Stock of the Issuer at a ratio of 1-for-2.466 upon closing of the initial public offering of the Issuer's common stock without payment of further consideration. The shares had no expiration date.
These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
These securities are held directly by RA Capital Nexus Fund II, L.P. (the "Nexus Fund II").
RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.